National Foundation for Cancer Research (NFCR) shared a post on LinkedIn:
“Understanding HER-2 the key to breast cancer subtypes.
From groundbreaking research to life-saving impact, Dr. Dennis Slamon joins NFCR CEO Dr. Sujuan Ba to discuss the pioneering work and collaboration that led to the eventual FDA approval of Herceptin, and what’s next in cancer research.
Listen now:
Proceed to the video attached to the post.
More posts featuring NFCR.